There’s widespread agreement on both sides of the aisle that big pharmaceutical companies have gamed the patent system and reform is overdue. The Senate bills will close loopholes that help keep drug prices high. Patients agree - let's get it done! David Mitchell, President and Founder of Patients For Affordable Drugs testified before the U.S. Senate Judiciary Committee on May 21 about the anticompetitive tactics deployed by drug companies to extend monopolies on branded products and urged bipartisan reforms that strike an “appropriate balance” between ensuring patents reward genuine innovation while facilitating timely competition to make prescription drugs more affordable for patients. #drugpricing #patentreform #healthequity
Merith Basey’s Post
More Relevant Posts
-
The U.S. Senate has unanimously approved a bill aimed at reducing the complexity of pharmaceutical patents, paving the way for increased competition in the industry. This move is a significant step towards reforming drug pricing and making generic and biosimilar drugs more accessible and affordable. A potential win for consumers looking for lower prescription drug costs! #PharmaPatents #DrugPricingReform
Senate Unanimously Passes Bill to Reduce Big Pharma Patent Thickets, Increase Competition | BioSpace
biospace.com
To view or add a comment, sign in
-
Are you interested in learning more about the ramifications of the upcoming changes to #German #Drug #Pricing and #Reimbursement laws? Our latest blog at Covington's Inside EU Life Sciences provides insights into what implications #Confidentiality Agreements in #Germany could have on #Pharmaceutical #Pricing. Let us share with you what #pharmaceutical companies can expect when #AMNOG gains one more layer of complexity. #MedicalResearchAct #Medizinforschungsgesetz #MFG #GermanPharmaStrategy #PharmaceuticalPricing #Pricing #MarketAccess #Legislativechanges #LifeSciences #Healthcare #Pharma Dr.iur. Dr.med. Adem Koyuncu | Covington & Burling LLP
Germany again to reform drug pricing and reimbursement laws – With “confidential reimbursements prices” that impede international reference pricing | Inside EU Life Sciences
https://www.insideeulifesciences.com
To view or add a comment, sign in
-
🚀 Legislative Update The U.S. Senate has unanimously passed the Affordable Prescriptions for Patients Act, introduced by Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT). This bipartisan legislation addresses abusive patent practices in the pharmaceutical industry, aiming to lower drug prices by: - Ending "patent thicketing" to allow affordable biosimilars to enter the market. - Balancing innovation incentives with preventing anti-competitive behaviors. - Receiving broad bipartisan support, indicating a strong consensus for reform. As the bill moves to the House, there is anticipation for further action to make medications more affordable. #HealthcareReform #AffordableDrugs #BipartisanSupport #PharmaReform
Senate Passes Bipartisan Bill to Lower Drug Prices and Combat Patent Abuses | PackGene Biotech
packgene.com
To view or add a comment, sign in
-
Common patenting tactic by drug companies may be illegal, FTC says In a new policy statement, the Federal Trade Commission (FTC) said it "intends to scrutinize" whether drug companies are inappropriately using a regulatory loophole to prevent their competitors from entering the market. The loophole in question allows drugmakers to patent different characteristics of their products and list those patents in a federal registry known as the Orange Book. FTC said it would explore whether companies are listing certain patents in the Orange Book that should not be there and as a result may impede generic competition. Listings in the Orange Book can be worth hundreds of millions of dollars for companies because they prohibit other firms from launching comparable generic products. In some instances, a listing instantly prohibits federal regulators from approving a competitor’s generic product for more than 2 years. Only some types of patents for medications can be listed in the Orange Book, including those safeguarding the drug itself or a process of using it; but some companies are listing their patents on inhalers, injector pens, and other devices that in some cases do not cite the medication they administer. According to an FTC official, the agency appears to be focusing on inhaler patents that may be infringing federal law. FTC Chair Lina Khan said at a public meeting on Thursday, "This seems to be a real problem, and one that could really be contributing to unaffordable medicines and drug products." https://lnkd.in/g2agZFrT
Common Patenting Tactic by Drug Companies May Be Illegal, F.T.C. Says
https://www.nytimes.com
To view or add a comment, sign in
-
BREAKING: A bipartisan group of lawmakers led by Senator Peter Welch introduce a new bill to address patent thickets. The bill aims to curb patent thickets and increase competition for branded medicines by limiting the number of patents a drugmaker can assert in litigation. "For decades, Big Pharma has exploited U.S. courts and the patent system through anti-competitive practices that prevent generic and biosimilar competitors from entering the market...This bipartisan legislation will be a step forward in the fight to stop pharmaceutical companies from abusing the patent system. That will lead to fair competition and lower prescription drug prices. Congress needs to keep working together to cut drug costs for families and streamline access to care." - Senator Peter Welch https://lnkd.in/e5Q7Hv6K
Welch, Braun, and Klobuchar Introduce Bipartisan Legislation to Streamline Drug Patent Litigation, Lower Cost of Prescription Drugs
https://www.welch.senate.gov
To view or add a comment, sign in
-
Patent protection for pharmaceuticals Particularly in industries where many expensive trials are required to develop new products, such as the pharmaceutical industry, patent protection plays a major role in creating a return of investment and companies try to extend it for as long as possible. On the other hand, generic manufacturers have an interest in patent protection expiring so that they can enter the market. Currently, some drug manufacturers are facing lawsuits alleging that they have misused patents to stop generic manufacturers in the US. #drugdevelopment #patents #generics
Lawsuit claims Boehringer misused US patents to delay asthma-drug rivals
reuters.com
To view or add a comment, sign in
-
In this clip from last month’s Senate Judiciary Committee hearing on drugmakers’ patenting and pricing tactics, Senator Cornyn plays right into the pharmaceutical industry’s hands by suggesting there’s a need for longer patent protected market monopolies. Extending market monopolies is the exact opposite of what Congress needs to do to bring down drug prices. Patents provide 20 years of monopoly from the date of filing. Pharmaceutical companies use a portion of that monopoly to fence off huge research areas to block competitors while they conduct R&D. Then they use the other portion of that monopoly to block competitors following commercial launch. Companies know that patent protection during the R&D phase is valuable but they want their patent clock to reset once they go to market. That’s not the bargain set by the patent system because the costs of the extended market monopoly would far outweigh the benefits it would provide to society. Congress must remember this and reject industry-driven narratives designed to exploit our pharmaceutical medicines system. If they had it their way, pharmaceutical companies would never want their patents to expire — and they'd probably argue that was good for society too.
To view or add a comment, sign in
-
Novo Nordisk Leads BioPharma Companies in Legal Challenge Against Drug Price Negotiation Provisions in Inflation Reduction Act Novo Nordisk, along with several other biopharma companies, is contesting the drug price negotiation provisions in the Inflation Reduction Act. A lawsuit has been filed by Novo alleging that the act infringes on their First and Fifth Amendment rights. Despite objections, these companies, including Novo, have consented to partake in the negotiation process and adhere […] #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical
Novo Nordisk Leads BioPharma Companies in Legal Challenge Against Drug Price Negotiation Provisions in Inflation Reduction Act
https://marketaccesstoday.com
To view or add a comment, sign in
-
Lilly Prevails as Judge Invalidates Teva's Patents in Emgality Dispute A federal judge in Massachusetts has overturned a $176.5 million jury verdict awarded to Teva Pharmaceuticals in a patent dispute with Eli Lilly over competing migraine medications. The judge ruled in favor of Lilly, stating that Teva had overreached by attempting to patent an entire class of drugs. This legal dispute dates back to 2018 when Teva alleged patent infringement by Lilly's Emgality, a migraine treatment. While Teva initially secured a victory, Emgality has achieved greater success in the market, generating $651 million in revenue in the previous year. If you want to stay informed about the latest developments in the pharmaceutical industry, visit Pharmtales. They provide up-to-date coverage of the Latest Pharma News. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #tevapatents #elililly #pharmaceuticalcompanies https://lnkd.in/d9t4CjRF
Lilly secures Emgality’s future after judge invalidates Teva’s patents
https://pharmtales.com
To view or add a comment, sign in
-
In a potential victory for drug pricing reform, the U.S. Senate on Thursday unanimously passed a pharma patent reform bill that could help promote generic and biosimilar competition for prescription drugs and lower their costs. The bill, sponsored by Sens. John Cornyn (R-Tex.) and Richard Blumenthal (D-Ct.), limits the number of patents that pharma companies can assert in infringement litigations. These limits are “subject to exceptions and waivers” such as how long the product has secured regulatory approval from the FDA. In addition to Coryn and Blumenthal’s bill, Sens. Peter Welch (D-Vt.), Mike Braun (R-Ind.) and Amy Klobuchar (D-Minn.) introduced similar legislation in January 2024 aiming to “streamline drug patent litigation” and promote competition to reduce drug prices. This bipartisan bill would allow pharma companies to assert only one patent per thicket in litigation. #biotech #biopharma #pharma #Senate #patent #drugpricing
Senate Unanimously Passes Bill to Reduce Big Pharma Patent Thickets, Increase Competition | BioSpace
biospace.com
To view or add a comment, sign in